NCT03348059

Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 103 (actual)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

The hypothesis was to check whether baseline anti-E1E2 antibodies could predict virological outcome in Hepatitis C virus (HCV)-infected patients receiving direct-acting antiviral treatment

Detailed description

Presence of anti-E1E2 antibodies was previously associated with spontaneous cure of hepatitis C virus (HCV). The hypothesis was to check whether baseline anti-E1E2 antibodies could predict virological outcome in HCV-infected patients receiving direct-acting antiviral treatment

Conditions

• Chronic Hepatitis c

Interventions

Type	Name	Description
DRUG	Direct-acting antiviral therapy	HCV patients received direct-acting antiviral treatment for 12 or 24 weeks

Timeline

• Start date: 2015-10-01
• Primary completion: 2016-11-30
• Completion: 2017-03-31
• First posted: 2017-11-20
• Last updated: 2017-11-20

Locations

1 site across 1 country: France